Novavax NVAX shares are trading higher on Friday after Cantor Fitzgerald raised its price target on the stock from $45 to $88.
The stock has regained investor interest amid a resurgence in coronavirus cases, as the company is working on a vaccine candidate.
Novavax is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases.
Novavax shares were trading up 6.55% at $63.15 at time of publication on Friday. The stock has a 52-week high of $64.32 and a 52-week low of $3.54.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
